Top 5 Most Read RNS's on Vox Markets for Monday 17th April 2023
Episode 1329, Apr 17, 2023, 06:41 AM
Top 5 Most Read RNS's on Vox Markets for Monday 17th April 2023
5. Synairgen #SNG - Notice of Full Year results
Synairgen will announce its preliminary statement of audited results for the year ended 31 December 2022 on Thursday 27 April 2023.
4. Polarean Imaging #POLX - Appointment of Dan Brague as consultant
Dan Brague will provide strategic advice to the Polarean commercial team to help refine its marketing and sales plans for the Company's drug device combination product, XENOVIEWTM (xenon Xe 129 hyperpolarised).
3. Harland & Wolff #HARL - Islandmagee Update – Concept Study Findings
The findings of the Report state that, subject to regulatory approval, hydrogen can be stored in the salt caverns and withdrawn to a hydrogen grid when required.
Additional capital expenditure required to integrate hydrogen compression, dehydration, and cooling into the Company's Islandmagee Gas Storage Facility would be approximately £168 million, with no incremental costs for drilling, leaching and creation of a salt cavern.
2. Omega Diagnostics #ODX - Trading Update
The Company expects to report revenues of £7.5m from continuing operations (2022: £8.6m), in line with the expected revenue range provided in the 18 January 2023 update.
With lower-than-expected production yields and higher raw material costs, the EBITDA loss for FY23 is now expected to be approximately £2.0m.
The year-end cash position was £5.0m, in-line with expectations, and more than adequate to allow Omega to deliver against its growth strategy from existing funds.
1. Avacta Group #AVCT - AVA3996 data poster presented at AACR
Avacta Group announces that it has presented pre-clinical data describing the novel pre|CISION proteasome inhibitor, AVA3996, at the 2023 American Association for Cancer Research (AACR) Annual Meeting in Florida, USA, one of the largest international cancer research meetings.
5. Synairgen #SNG - Notice of Full Year results
Synairgen will announce its preliminary statement of audited results for the year ended 31 December 2022 on Thursday 27 April 2023.
4. Polarean Imaging #POLX - Appointment of Dan Brague as consultant
Dan Brague will provide strategic advice to the Polarean commercial team to help refine its marketing and sales plans for the Company's drug device combination product, XENOVIEWTM (xenon Xe 129 hyperpolarised).
3. Harland & Wolff #HARL - Islandmagee Update – Concept Study Findings
The findings of the Report state that, subject to regulatory approval, hydrogen can be stored in the salt caverns and withdrawn to a hydrogen grid when required.
Additional capital expenditure required to integrate hydrogen compression, dehydration, and cooling into the Company's Islandmagee Gas Storage Facility would be approximately £168 million, with no incremental costs for drilling, leaching and creation of a salt cavern.
2. Omega Diagnostics #ODX - Trading Update
The Company expects to report revenues of £7.5m from continuing operations (2022: £8.6m), in line with the expected revenue range provided in the 18 January 2023 update.
With lower-than-expected production yields and higher raw material costs, the EBITDA loss for FY23 is now expected to be approximately £2.0m.
The year-end cash position was £5.0m, in-line with expectations, and more than adequate to allow Omega to deliver against its growth strategy from existing funds.
1. Avacta Group #AVCT - AVA3996 data poster presented at AACR
Avacta Group announces that it has presented pre-clinical data describing the novel pre|CISION proteasome inhibitor, AVA3996, at the 2023 American Association for Cancer Research (AACR) Annual Meeting in Florida, USA, one of the largest international cancer research meetings.